107
107 years of development
119
Vaccine coverage over 119 countries and regions
15
15 innovative drugs under R&D
3
3 production workshops with a hundred-of-million production scale of COVID-19 Inactivated Vaccine (Vero Cell)
News Recommendation
The bOPV Product of BIBP Successfull
2026-04-03
Global Business Unitparticipated in and supported the inspection process throughout. Nigeria is the most populous country in Africa. As one of the most influential pharmaceutical regulatory authorities ...
View More+
Achievements, Synergy, Responsibilit
2026-01-20
To comprehensively review and summarize the annual work, systematically assess the performance capabilities and effectiveness of middle-level managers, further unify thinking, strengthen confidence, rise to challenges, and propel the co...
View More+
Communication Fosters Consensus, Lea
2025-10-30
Secretary Li Xinguo, Financial Director Zhang Hui, Deputy General Manager Yang Ming, and managers from relevant departments. During the event, delegates visited the A Centennial Exhibition Hall of China Biological Products ...
View More+About Company
Beijing Institute of Biological Products Co., Ltd. (BIBP), a subsidiary of China National Biotec Group Company Limited (CNBG), China National Pharmaceutical Group Co., Ltd. (Sinopharm), is engaged in the research, production and marketing of vaccines, diagnostic preparations and other biological products, with a registered capital of CNY 2.3 billions. The history of BIBP can be traced back to 1919 when National Epidemic Prevention Bureau was established , representing the cradle of biological products for The People's Republic of China.
Achievements More+Scientific Research and Innovation
